Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Alchemia treats first patient in pivotal phase III HA-irinotecan trial

Jan. 5, 2012

Phase II trial assesses proprietary Exelixis drug in metastatic breast cancer

Jan. 5, 2012

Dual ERK inhibitor shows promise as triple-negative breast cancer therapy

Jan. 5, 2012

Phase II results disclosed on PD-0332991

Jan. 5, 2012

Phase II data presented on PEGylated therapy in previously treated metastatic breast cancer

Jan. 5, 2012

Tragara multikinase inhibitor may be beneficial to treat triple-negative breast cancer

Jan. 5, 2012

Phase I/II CF-102 trials meet primary endpoints

Jan. 4, 2012

Yakult Honsha begins phase I/II study of perifosine in Japan

Jan. 4, 2012

SNS01-T shows synergy with lenalidomide in human cancer model

Jan. 4, 2012

Interim data presented from phase I/II trial of neratinib plus capecitabine in breast cancer

Jan. 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...